1. Home
  2. PRPO vs EVAX Comparison

PRPO vs EVAX Comparison

Compare PRPO & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRPO
  • EVAX
  • Stock Information
  • Founded
  • PRPO N/A
  • EVAX 2008
  • Country
  • PRPO United States
  • EVAX Denmark
  • Employees
  • PRPO N/A
  • EVAX N/A
  • Industry
  • PRPO Biotechnology: Laboratory Analytical Instruments
  • EVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PRPO Industrials
  • EVAX Health Care
  • Exchange
  • PRPO Nasdaq
  • EVAX Nasdaq
  • Market Cap
  • PRPO 9.9M
  • EVAX 8.7M
  • IPO Year
  • PRPO N/A
  • EVAX 2021
  • Fundamental
  • Price
  • PRPO $6.89
  • EVAX $2.34
  • Analyst Decision
  • PRPO
  • EVAX Strong Buy
  • Analyst Count
  • PRPO 0
  • EVAX 3
  • Target Price
  • PRPO N/A
  • EVAX $33.33
  • AVG Volume (30 Days)
  • PRPO 6.8K
  • EVAX 6.9M
  • Earning Date
  • PRPO 03-28-2025
  • EVAX 03-26-2025
  • Dividend Yield
  • PRPO N/A
  • EVAX N/A
  • EPS Growth
  • PRPO N/A
  • EVAX N/A
  • EPS
  • PRPO N/A
  • EVAX N/A
  • Revenue
  • PRPO $17,411,000.00
  • EVAX $3,295,000.00
  • Revenue This Year
  • PRPO $75.18
  • EVAX $4,845.21
  • Revenue Next Year
  • PRPO N/A
  • EVAX $30.30
  • P/E Ratio
  • PRPO N/A
  • EVAX N/A
  • Revenue Growth
  • PRPO 31.31
  • EVAX N/A
  • 52 Week Low
  • PRPO $4.31
  • EVAX $2.22
  • 52 Week High
  • PRPO $7.20
  • EVAX $23.70
  • Technical
  • Relative Strength Index (RSI)
  • PRPO 61.15
  • EVAX 38.89
  • Support Level
  • PRPO $6.65
  • EVAX $2.22
  • Resistance Level
  • PRPO $6.90
  • EVAX $4.05
  • Average True Range (ATR)
  • PRPO 0.23
  • EVAX 1.10
  • MACD
  • PRPO 0.02
  • EVAX -0.02
  • Stochastic Oscillator
  • PRPO 84.72
  • EVAX 2.11

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

About EVAX Evaxion Biotech

Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.

Share on Social Networks: